204 related articles for article (PubMed ID: 11001791)
1. Synergistic heterozygosity: disease resulting from multiple partial defects in one or more metabolic pathways.
Vockley J; Rinaldo P; Bennett MJ; Matern D; Vladutiu GD
Mol Genet Metab; 2000; 71(1-2):10-8. PubMed ID: 11001791
[TBL] [Abstract][Full Text] [Related]
2. Synergistic heterozygosity in mice with inherited enzyme deficiencies of mitochondrial fatty acid beta-oxidation.
Schuler AM; Gower BA; Matern D; Rinaldo P; Vockley J; Wood PA
Mol Genet Metab; 2005 May; 85(1):7-11. PubMed ID: 15862275
[TBL] [Abstract][Full Text] [Related]
3. Clear relationship between ETF/ETFDH genotype and phenotype in patients with multiple acyl-CoA dehydrogenation deficiency.
Olsen RK; Andresen BS; Christensen E; Bross P; Skovby F; Gregersen N
Hum Mutat; 2003 Jul; 22(1):12-23. PubMed ID: 12815589
[TBL] [Abstract][Full Text] [Related]
4. Genetic risk factors associated with lipid-lowering drug-induced myopathies.
Vladutiu GD; Simmons Z; Isackson PJ; Tarnopolsky M; Peltier WL; Barboi AC; Sripathi N; Wortmann RL; Phillips PS
Muscle Nerve; 2006 Aug; 34(2):153-62. PubMed ID: 16671104
[TBL] [Abstract][Full Text] [Related]
5. Recent developments in the investigation of inherited metabolic disorders using cultured human cells.
Roe CR; Roe DS
Mol Genet Metab; 1999 Oct; 68(2):243-57. PubMed ID: 10527676
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic assessment and long-term follow-up of 13 patients with Very Long-Chain Acyl-Coenzyme A dehydrogenase (VLCAD) deficiency.
Laforêt P; Acquaviva-Bourdain C; Rigal O; Brivet M; Penisson-Besnier I; Chabrol B; Chaigne D; Boespflug-Tanguy O; Laroche C; Bedat-Millet AL; Behin A; Delevaux I; Lombès A; Andresen BS; Eymard B; Vianey-Saban C
Neuromuscul Disord; 2009 May; 19(5):324-9. PubMed ID: 19327992
[TBL] [Abstract][Full Text] [Related]
7. MS/MS-based newborn and family screening detects asymptomatic patients with very-long-chain acyl-CoA dehydrogenase deficiency.
Spiekerkoetter U; Sun B; Zytkovicz T; Wanders R; Strauss AW; Wendel U
J Pediatr; 2003 Sep; 143(3):335-42. PubMed ID: 14517516
[TBL] [Abstract][Full Text] [Related]
8. Mutation analysis in mitochondrial fatty acid oxidation defects: Exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship.
Gregersen N; Andresen BS; Corydon MJ; Corydon TJ; Olsen RK; Bolund L; Bross P
Hum Mutat; 2001 Sep; 18(3):169-89. PubMed ID: 11524729
[TBL] [Abstract][Full Text] [Related]
9. [Carnitine deficiency in inborn errors of metabolism].
Sela BA; Lerman-Sagie T; Berkovitz M
Harefuah; 1997 Nov; 133(10):419-23, 504. PubMed ID: 9418309
[TBL] [Abstract][Full Text] [Related]
10. [Changes in carnitine metabolism. A case report about probable partial deficiency of muscle carnitine palmitoyltransferase].
De Prà M; Oberti F; De Benedittis A
Pediatr Med Chir; 1990; 12(4):397-403. PubMed ID: 2075107
[TBL] [Abstract][Full Text] [Related]
11. Neurological diseases in disorders of organic acids.
Marsden DL; Nyhan WL
Curr Opin Neurol Neurosurg; 1992 Jun; 5(3):349-54. PubMed ID: 1623263
[TBL] [Abstract][Full Text] [Related]
12. Carnitine palmitoyltransferase II (CPT II) deficiency: genotype-phenotype analysis of 50 patients.
Joshi PR; Deschauer M; Zierz S
J Neurol Sci; 2014 Mar; 338(1-2):107-11. PubMed ID: 24398345
[TBL] [Abstract][Full Text] [Related]
13. Combined methylmalonic aciduria and homocystinuria (cblC): phenotype-genotype correlations and ethnic-specific observations.
Morel CF; Lerner-Ellis JP; Rosenblatt DS
Mol Genet Metab; 2006 Aug; 88(4):315-21. PubMed ID: 16714133
[TBL] [Abstract][Full Text] [Related]
14. Carnitine palmityl transferase I deficiency.
Al-Aqeel AI; Rashed MS; Ruiter JP; Al-Husseini HF; Al-Amoudi MS; Wanders RJ
Saudi Med J; 2001 Nov; 22(11):1025-9. PubMed ID: 11744980
[TBL] [Abstract][Full Text] [Related]
15. [Biochemical diagnosis of rare hereditary metabolic disorders. Experiences from a patient sample of the Innsbruck University Pediatric Clinic 1984-1987].
Sperl W
Padiatr Padol; 1990; 25(3):157-67. PubMed ID: 2381732
[TBL] [Abstract][Full Text] [Related]
16. Neonatal screening for very long-chain acyl-coA dehydrogenase deficiency: enzymatic and molecular evaluation of neonates with elevated C14:1-carnitine levels.
Liebig M; Schymik I; Mueller M; Wendel U; Mayatepek E; Ruiter J; Strauss AW; Wanders RJ; Spiekerkoetter U
Pediatrics; 2006 Sep; 118(3):1065-9. PubMed ID: 16950999
[TBL] [Abstract][Full Text] [Related]
17. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.
Djouadi F; Aubey F; Schlemmer D; Ruiter JP; Wanders RJ; Strauss AW; Bastin J
Hum Mol Genet; 2005 Sep; 14(18):2695-703. PubMed ID: 16115821
[TBL] [Abstract][Full Text] [Related]
18. Novel mutations in CPT 1A define molecular heterogeneity of hepatic carnitine palmitoyltransferase I deficiency.
Bennett MJ; Boriack RL; Narayan S; Rutledge SL; Raff ML
Mol Genet Metab; 2004 May; 82(1):59-63. PubMed ID: 15110323
[TBL] [Abstract][Full Text] [Related]
19. Clinical features and new molecular findings in Carnitine Palmitoyltransferase II (CPT II) deficiency.
Corti S; Bordoni A; Ronchi D; Musumeci O; Aguennouz M; Toscano A; Lamperti C; Bresolin N; Comi GP
J Neurol Sci; 2008 Mar; 266(1-2):97-103. PubMed ID: 17936304
[TBL] [Abstract][Full Text] [Related]
20. [Three congenital metabolic diseases in the Faeroe Islands. Incidence, clinical and molecular genetic characteristics of Faeroese children with glycogen storage disease type IIIA, carnitine transporter deficiency and holocarboxylase synthetase deficiency].
Joensen F; Steuerwald EU; Rasmussen NH
Ugeskr Laeger; 2006 Feb; 168(7):667-70. PubMed ID: 16494802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
